Population survival impact of new targeted and immune based therapies for metastatic or unresectable melanoma
Introduction New classes of drugs for metastatic or unresectable melanoma (MM) have shown improved survival in randomized trials (e.g., anti-CTLA-4, anti-PD-1, BRAF/MEK inhibitors). We sought to describe uptake of these new drugs and their impact on population-based survival outcomes of MM. Objec...
Main Authors: | Paul Nguyen, Tara Baetz, Christopher Booth, Elizabeth Eisenhauer, Timothy Hanna |
---|---|
Format: | Article |
Language: | English |
Published: |
Swansea University
2018-08-01
|
Series: | International Journal of Population Data Science |
Online Access: | https://ijpds.org/article/view/639 |
Similar Items
-
FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma
by: Zainab Abbas, et al.
Published: (2023-09-01) -
Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma
by: Adi Kartolo, et al.
Published: (2022-03-01) -
Circulating melanoma cells and survival in metastatic melanoma.
by: Rao, C, et al.
Published: (2011) -
Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
by: Doris Helbig, et al.
Published: (2022-11-01) -
Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
by: Justin Tong, et al.
Published: (2022-10-01)